There could be less of an impact on insulin pumps, because that market treats primarily type-1 diabetics, where GLP-1 medications do not play a role
Were doing all the things necessary to keep everyone safe. Steps to prevent the spread of illness at St
Differentiation therapy targeting the -catenin/CBP interaction in pancreatic cancer
These results illustrate that A
That timing is a clue that behavior, not the patch, is doing the heavy lifting
This is a head-to-head comparison, and [orforglipron] is certainly quite effective. According to the treatment-regimen estimand, weight loss at 1 year was 6.1% with orforglipron 12 mg, 8.2% with orforglipron 36 mg, 3.9% with oral semaglutide 7 mg and 5.3% with oral semaglutide 14 mg